elacridar has been researched along with Colonic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fukumura, T; Hatori, A; Kawamura, K; Nengaki, N; Ogawa, M; Wakisaka, H; Yamasaki, T; Yanamoto, K; Yoshida, Y; Yui, J; Zhang, MR | 1 |
Du Vignaud, P; Grand-Perret, T; Hyafil, F; Vergely, C | 1 |
2 other study(ies) available for elacridar and Colonic Neoplasms
Article | Year |
---|---|
PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Topics: Acridines; Adenocarcinoma; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Western; Caco-2 Cells; Carbon Radioisotopes; Colonic Neoplasms; Dogs; Humans; Ligands; Male; Mice; Neoplasm Proteins; Positron-Emission Tomography; Tetrahydroisoquinolines; Tomography, Emission-Computed, Single-Photon | 2010 |
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Topics: Acridines; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Female; Humans; Isoquinolines; Leukemia P388; Mice; Mice, Inbred DBA; Ovary; Tetrahydroisoquinolines; Tumor Cells, Cultured | 1993 |